Comparison 2. Children with fever and neutropenia: caspofungin versus liposomal amphotericin B (3 mg/kg).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality (all cause)	1	81	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Mortality (related to fungal infection)	1	81	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Complete resolution of fungal infection	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Partial resolution of fungal infection	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Resolution of fever in suspected fungal infection	1	81	Risk Ratio (M‐H, Random, 95% CI)	1.34 [0.70, 2.56]
6 Progression of disease requiring change / addition of an antifungal agent	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
7 Breakthrough fungal infection requiring change / addition of an antifungal agent	1	81	Risk Ratio (M‐H, Random, 95% CI)	0.15 [0.01, 3.61]
8 Any clinically significant adverse reactions attributed to the antifungal agent resulting in discontinuation, dose reduction or change in therapy	1	82	Risk Ratio (M‐H, Random, 95% CI)	0.31 [0.06, 1.74]
9 Any clinically significant adverse reactions attributed to the antifungal agent (total)	1	82	Risk Ratio (M‐H, Random, 95% CI)	1.04 [0.64, 1.72]
10 Nephrotoxicity	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
11 Hypokalaemia	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
12 Hepatotoxicity	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
13 Infusion‐related reactions	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
14 Gastrointestinal toxicity	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
15 Neurological disturbances	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
16 Haematological disturbances	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
17 Length of Stay	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
18 Quality of Life	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
19 Cost	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]